New Warning Issued for Stryker Hip Implants

Tuesday, October 25, 2016
Stryker Hip

Stryker Orthopedics, a market leader in hip and knee replacement implants, has sold millions of devices in recent decades. However, they have also recalled several of those implants due to serious health risks, with at least four recalls issued since 2009.

This summer, Stryker took the first step toward what many believe may be their latest hip recall when they issued a private letter to doctors warning of risks with their LFit V40 femoral head, which is used on several hip replacement models.

On August 29, 2016, Stryker sent a Product Field Action Notification to physicians warning that the LFit V40 femoral heads may have a higher rate of taper lock failure complications that can cause device separation, fractures and metallic debris.

These femoral heads are used on the following models:

  • LFit V40 femoral heads between 36mm and 44mm
  • Accolade TMZF implants
  • Accolade 2 implants
  • Meridian implants
  • Citation implants

Patients with these defective implants have a greater risk of bone necrosis, metallic poisoning and devices becoming dislocated. They also likely received their implants without any warning of these dangers.

With repeated implant product recalls over the past decade, Stryker has also faced thousands of hip replacement lawsuits from affected patients. Stemming from their recall of the ABG II and Rejuvenate implants, the company faced nearly 4,500 claims.

In November of 2014, Stryker agreed to pay $1.43 billion to settle pending lawsuits over Rejuvenate and ABG II hips. Lawyers believe the latest warning associated with the LFit, Accolade, Meridian and Citation hips may lead to even more lawsuits.

If you or a loved one received a Stryker Accolade, Meridian or Citation metal hip implant, it’s important to talk with a lawyer about your legal rights.

Contact DrugNews today for more information about Stryker hip recalls or to speak with a lawyer at no cost.

Stryker Hip

Other drugs and devices in the news:

Tuesday, April 14, 2020
Sudden Rise in Elmiron Eye Disease Cases Raises Questions

Elmiron is a mild blood-thinner drug that has been around since 1996 and is prescribed to treat bladder pain or inflammation, a condition called interstitial cystitis.

Monday, April 13, 2020
Asbestos Mesothelioma
Estimated $30 Billion Left Unclaimed in Asbestos Victim Funds

Since many of the companies that sold asbestos or used it in their products have long since gone out of business, people who are diagnosed with asbestos-related cancers often think it’s too late to file a lawsuit.

Get in touch with us.

Call, email or live chat with us today to see how we can help.

Need a quick answer? Call us!
Reach out to us by email.
live chat with DrugNews
We are here to help now